MA22842A1 - Procede de preparation de compositions de vaccin. - Google Patents

Procede de preparation de compositions de vaccin.

Info

Publication number
MA22842A1
MA22842A1 MA23137A MA23137A MA22842A1 MA 22842 A1 MA22842 A1 MA 22842A1 MA 23137 A MA23137 A MA 23137A MA 23137 A MA23137 A MA 23137A MA 22842 A1 MA22842 A1 MA 22842A1
Authority
MA
Morocco
Prior art keywords
preparation
vaccine compositions
vaccine
compositions
Prior art date
Application number
MA23137A
Other languages
English (en)
Inventor
Hauser Pierre
Voet Pierre
Marie Josephe Claude Nathalie
Thiriart Clothide
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA22842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MA22842A1 publication Critical patent/MA22842A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA23137A 1992-03-27 1993-03-23 Procede de preparation de compositions de vaccin. MA22842A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine

Publications (1)

Publication Number Publication Date
MA22842A1 true MA22842A1 (fr) 1993-10-01

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23137A MA22842A1 (fr) 1992-03-27 1993-03-23 Procede de preparation de compositions de vaccin.

Country Status (27)

Country Link
EP (1) EP0633784B2 (fr)
JP (1) JP3470719B2 (fr)
KR (1) KR100270134B1 (fr)
CN (1) CN1072963C (fr)
AP (1) AP570A (fr)
AT (1) ATE146678T1 (fr)
AU (4) AU3751693A (fr)
CA (1) CA2132833C (fr)
CZ (1) CZ283424B6 (fr)
DE (1) DE69306940T3 (fr)
DK (1) DK0633784T4 (fr)
ES (1) ES2098029T5 (fr)
FI (1) FI110843B (fr)
GR (1) GR3022174T3 (fr)
HU (1) HU221253B1 (fr)
IL (1) IL105161A (fr)
MA (1) MA22842A1 (fr)
MY (1) MY111880A (fr)
NO (1) NO309458B1 (fr)
NZ (1) NZ249868A (fr)
RU (1) RU2121849C1 (fr)
SA (1) SA93130573B1 (fr)
SG (1) SG48375A1 (fr)
SI (1) SI9300149B (fr)
SK (1) SK280160B6 (fr)
UA (1) UA44688C2 (fr)
WO (1) WO1993019780A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
RU2116086C1 (ru) * 1997-08-19 1998-07-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Способ вакцинации против вирусного гепатита b
NZ506602A (en) * 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
RU2135209C1 (ru) * 1998-07-17 1999-08-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Фармацевтическая композиция для иммунопрофилактики вирусного гепатита b
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
CA2628152C (fr) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
EP2476433A1 (fr) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Composition immunogène
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (fr) 2006-09-11 2025-09-24 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d'oeufs
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2690708A1 (fr) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccin
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
DK2403507T3 (en) 2009-03-05 2018-06-06 Jenny Colleen Mccloskey TREATMENT OF INFECTION
CA2768186A1 (fr) 2009-07-15 2011-01-20 Novartis Ag Compositions a base de proteine f du vrs et procedes de fabrication associes
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2646459B1 (fr) 2010-12-02 2020-01-08 Bionor Immuno AS Conception d'échafaudage peptidique
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
WO2012103361A1 (fr) 2011-01-26 2012-08-02 Novartis Ag Régime d'immunisation contre le vrs
CA2835644C (fr) 2011-05-13 2021-06-15 Novartis Ag Antigenes de pre-fusion f du vrs
IN2014KN02769A (fr) 2012-06-06 2015-05-08 Bionor Immuno As
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
WO2020099927A1 (fr) 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Compositions immunogènes pour le traitement de l'hépatite b
WO2021160887A1 (fr) 2020-02-14 2021-08-19 Immunor As Vaccin contre le coronavirus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
WO1989012641A1 (fr) * 1988-06-17 1989-12-28 Genelabs Incorporated Agent viral de l'hepatite non-a/non-b transmis par voie enterique
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0414374B1 (fr) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigènes ainsi que les méthodes pour leur préparation
WO1991004262A1 (fr) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan Nouveaux isolats du virus de l'hepatite c
SU1678373A1 (ru) * 1989-10-18 1991-09-23 Киевский Научно-Исследовательский Институт Эпидемиологии И Инфекционных Болезней Им.Л.В.Громашевского Способ иммунокоррекции при зат жных формах гепатита
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
EP0563091A1 (fr) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B

Also Published As

Publication number Publication date
AU3397499A (en) 1999-08-19
NZ249868A (en) 1997-03-24
NO309458B1 (no) 2001-02-05
EP0633784A1 (fr) 1995-01-18
FI110843B (fi) 2003-04-15
DE69306940T2 (de) 1997-06-26
KR100270134B1 (ko) 2000-10-16
CZ283424B6 (cs) 1998-04-15
CZ235594A3 (en) 1995-02-15
ATE146678T1 (de) 1997-01-15
GR3022174T3 (en) 1997-03-31
CA2132833C (fr) 2007-03-06
HU9402758D0 (en) 1994-12-28
SK115294A3 (en) 1995-06-07
CN1072963C (zh) 2001-10-17
EP0633784B2 (fr) 2001-10-17
SI9300149A (en) 1993-12-31
DK0633784T4 (da) 2001-12-31
MY111880A (en) 2001-02-28
DE69306940T3 (de) 2002-09-19
FI944442A0 (fi) 1994-09-26
HU221253B1 (en) 2002-09-28
IL105161A (en) 1998-08-16
DK0633784T3 (da) 1997-01-20
ES2098029T5 (es) 2002-03-16
KR950700757A (ko) 1995-02-20
SI9300149B (sl) 2003-02-28
NO943571L (no) 1994-11-14
RU94042386A (ru) 1996-08-20
JP3470719B2 (ja) 2003-11-25
UA44688C2 (uk) 2002-03-15
EP0633784B1 (fr) 1996-12-27
CA2132833A1 (fr) 1993-10-14
AU3751693A (en) 1993-11-08
CN1085805A (zh) 1994-04-27
HUT69931A (en) 1995-09-28
AP570A (en) 1996-11-29
HK1003218A1 (en) 1998-10-16
JPH07505372A (ja) 1995-06-15
AP9300502A0 (en) 1993-04-30
WO1993019780A1 (fr) 1993-10-14
RU2121849C1 (ru) 1998-11-20
DE69306940D1 (de) 1997-02-06
IL105161A0 (en) 1993-07-08
AU6445796A (en) 1996-11-07
SA93130573B1 (ar) 2004-08-31
SG48375A1 (en) 1998-04-17
SK280160B6 (sk) 1999-09-10
AU1000802A (en) 2002-02-21
NO943571D0 (no) 1994-09-26
AU767755B2 (en) 2003-11-20
ES2098029T3 (es) 1997-04-16
FI944442L (fi) 1994-09-26

Similar Documents

Publication Publication Date Title
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
MA23850A1 (fr) Procede de preparation de compositions vaccinantes
MA23918A1 (fr) Procede de preparation de compositions vaccinantes
MA23814A1 (fr) Procede de preparation de compositions vaccinantes
MA22894A1 (fr) Procede de preparation d'un vaccin.
MA23143A1 (fr) Procede pour la preparation de compositions vaccinantes .
MA23395A1 (fr) Procede de preparation de nouvelles formulations
FI914174A7 (fi) Menetelmä piperidyylialkyyliamiinien valmistamiseksi
MA22471A1 (fr) Procede de production de vaccin
MA24291A1 (fr) Procede pour la preparation de compositions de vaccin
MA23118A1 (fr) Procede pour la preparation de compositions de vaccins contre la grippe .
MA21977A1 (fr) Procede de preparation de compositions bitumineuses .
FR2722210B1 (fr) Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
IS3814A (is) Aðferð til framleiðslu á lyfjablöndum
FR2664274B1 (fr) Procede de preparation de sulfates cycliques.
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
ITMI931680A1 (it) Procedimento per la preparazione di alcansolfonammidi
MA21854A1 (fr) Procede de preparation de phosphonomethyl thioethoxypurines .
FI933755A7 (fi) Menetelmä trans-piperidiini-2,5-dikarboksylaattien valmistamiseksi
FR2695645B1 (fr) Procédé de préparation de polyaminoborazines.
FI913464A7 (fi) Menetelmä 1-hydroksimetyylipyratsolien valmistamiseksi
IT9067657A1 (it) Procedimento per la preparazione di alfa-alchil-lattoni.
FI922125A7 (fi) Mikrobiologinen menetelmä 5-hydroksipyratsiinikarboksyylihapon valmistamiseksi
FI923866A7 (fi) Menetelmä 1-hydroksialkyyli-5-nitroimidatsolien valmistamiseksi
FI930237A7 (fi) Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi